Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas

Table 1

Baseline characteristics of the cohort.

Characteristics	n (%)	Median	Range
Age at transplant, years	50 (100%)	57.5	(23–73)
Sex
Female	17 (34%)
Male	33 (66%)
Lymphoma type
DLBCL	34 (68%)
Mantle cell	10 (20%)
T-cell	5 (10%)
Follicular	1 (2%)
Prognostic factors at diagnosis
Extra nodal sites
0	33 (66%)
1	15 (30%)
2	2 (4%)
LDH (U/L)	50 (100%)	209	(150–1515)
Performance status
0	31 (62%)
1	17 (34%)
2	2 (4%)
Stage
I	6 (12%)
II	5 (10%)
III	8 (16%)
IV	31 (62%)
IPI score
Age at transplant, years
≥60	23 (46%)
<60	27 (56%)
LDH
Normal	21 (42%)
Abnormal	29 (58%)
Extra nodal sites
≥2	2 (4%)
<2	48 (96%)
Performance status
≥2	2 (4%)
<2	48 (96%)
Stage
I/II	11 (22%)
III/IV	39 (78%)
Infused CD34 cells × 10^6/kg	50 (100%)	4.68	(2.03–8.56)
Infused A-ALC × 10^9 lymphocytes/kg	50 (100%)	0.55	(0.08–1.5)
ALC-15 cells/𝜇L	50 (100%)	670	(2.0–4,500)
NK-15 cells/𝜇L	50 (100%)	103	(10–999)
Mono-15 cells/𝜇L	50 (100%)	860	(2.0–4,500)
Infused A-mono × 10^9 monocytes/kg	50 (100%)	0.58	(0.08–1.5)

A-ALC: autograft, absolute lymphocyte count; ALC-15: absolute lymphocyte count at day 15 post transplant; A-mono: autograft absolute monocyte count; DLBCL: diffuse large B-cell lymphoma; IPI: International prognostic index; LDH: lactate dehydrogenase; Mono-15: absolute monocyte count at day 15 post transplant; NK-15: absolute natural killer cell count at day 15 post transplant.